X4 Pharmaceuticals (NASDAQ:XFOR) Earns Buy Rating from HC Wainwright

X4 Pharmaceuticals (NASDAQ:XFOR)‘s stock had its “buy” rating reaffirmed by research analysts at HC Wainwright in a report released on Tuesday,Benzinga reports. They currently have a $1.50 price objective on the stock. HC Wainwright’s target price would indicate a potential upside of 225.31% from the stock’s current price.

Separately, Stifel Nicolaus cut their price objective on X4 Pharmaceuticals from $5.00 to $4.00 and set a “buy” rating on the stock in a research note on Thursday, November 14th.

X4 Pharmaceuticals Stock Up 1.2 %

NASDAQ:XFOR opened at $0.46 on Tuesday. The firm’s 50 day simple moving average is $0.55 and its 200 day simple moving average is $0.61. The company has a market cap of $78.64 million, a PE ratio of -5.12 and a beta of 0.14. X4 Pharmaceuticals has a one year low of $0.26 and a one year high of $1.60. The company has a debt-to-equity ratio of 1.26, a current ratio of 4.89 and a quick ratio of 4.80.

Hedge Funds Weigh In On X4 Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in XFOR. Verition Fund Management LLC bought a new position in X4 Pharmaceuticals during the third quarter worth $30,000. SG Americas Securities LLC acquired a new stake in shares of X4 Pharmaceuticals in the 3rd quarter worth about $37,000. XTX Topco Ltd bought a new position in shares of X4 Pharmaceuticals in the second quarter valued at approximately $65,000. Rhumbline Advisers lifted its stake in X4 Pharmaceuticals by 14.6% during the 2nd quarter. Rhumbline Advisers now owns 187,246 shares of the company’s stock valued at $109,000 after acquiring an additional 23,831 shares in the last quarter. Finally, Jane Street Group LLC lifted its position in shares of X4 Pharmaceuticals by 103.4% during the third quarter. Jane Street Group LLC now owns 248,447 shares of the company’s stock valued at $166,000 after purchasing an additional 126,296 shares in the last quarter. 72.03% of the stock is owned by institutional investors and hedge funds.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.